Zugänglichkeit
Hilfe
Animation
Zugänglichkeit
Patient and Provider walking down a hallway. Provider's hand is on the back of the patient

Medication-Assisted Treatment (MAT)

We're committed to supporting the complete care of patients with opioid use disorder (OUD) on their recovery journeys. Our MAT panels are designed to monitor patients on buprenorphine or buprenorphine/naloxone (e.g., Suboxone®, Subutex®, Zubsolv ®). We also offer panels suitable for methadone or naltrexone MAT.

MAT Screening Options(Opens in a new window) Watch MAT Webinar
supporting image

What is medication-assisted treatment?

MAT is the use of medications in combination with counseling and behavioral therapies to treat OUD. Buprenorphine is one of the three drugs currently approved by the Food and Drug Administration (FDA) for the treatment of OUD.1

With Labcorp’s MAT drug testing portfolio—including three primary panels, individual drug class options and personal customization—you can support patients taking buprenorphine or buprenorphine/naloxone for MAT as they navigate the path to recovery.

We strive to provide exceptional customer service, patient care and consultative technical expertise

 

  • Extensive managed care network

  • Clinical drug testing support hotline: 877-474-5767

  • More than 2,000 patient service centers nationwide

  • Local courier services

  • Comprehensive EHR/EMR interfacing capabilities

Your source for monitoring buprenorphine/naloxone treatment for OUD

Monitoring the norbuprenorphine-to-buprenorphine ratio over time can help confirm that your patient is taking their medication consistently as prescribed and detect urine spiking.

Labcorp MAT drug test options feature:
 

  • Optional enhanced reporting (by adding Test No. 702880), including summaries of patient medication compliance and cumulative testing results* 

  • Four-week sample retention for optimizing add-on testing opportunities 

  • Optimized detection thresholds for MAT patients

  • Compliance with SAMHSA 42 CFR Part 2 confidentiality regulation

     

*Not available as part of Test No. 705540

Watch our webinars

MAT screening options

Number Name
705540 Drug Screen Only 18, Urine, Medication Assisted Treatment (MAT)
701957 Buprenorphine MAT1, Urine, Medication Assisted Treatment (MAT)
701985 Buprenorphine Medication Assisted Treatment Monitoring 2, Urine


Optional add-on testing

 

Number Name
702515 Ketamine, MS Confirm, Urine, Medication Assisted Treatment (MAT)
702549 Kratom, Screen with Confirmation, Urine, Medication Assisted Treatment (MAT)
702550 Methylphenidate, Screen With Confirmation, Urine, Medication Assisted Treatment (MAT)
702518 Naltrexone, MS Confirm, Urine, Medication Assisted Treatment (MAT)
702551 Nicotine Metabolite, Screen With Confirmation, Medication Assisted Treatment (MAT)


General health testing

Guideline-recommended baseline tests for OUD treatment2,3

Number Name
303754 Electrolyte Panel
322758 Metabolic Panel (8), Basic
005009 Complete Blood Count (CBC) With Differential, Reflex to Peripheral Smear Review
322755 Hepatic Function Panel (7)
001958 γ-Glutamyl Transferase (GGT)
005199 Prothrombin Time (PT)
Number Name
303756 Lipid Panel
003772 Urinalysis, Complete With Microscopic Examination
004036 Pregnancy Test, Urine
144552 Viral Hepatitis Screening and Diagnosis (HAV and HBV)
083935 HIV p24 Antigen/Antibody With Reflex to Confirmation
182879 QuantiFERON®-TB Gold Plus
144050 Hepatitis C Virus (HCV) Antibody With Reflex to Quantitative Real-time PCR

References:

  1. Food and Drug Administration (FDA). Information about Medication-Assisted Treatment (MAT). Accessed June 7, 2023. https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.
  3. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update [published correction appears in J Addict Med. 2020 May/Jun;14(3):267]. J Addict Med. 2020;14(2S Suppl 1):1-91. doi:10.1097/ADM.0000000000000633.